COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
Fluvoxamine study #2 of 3
11/12 Early treatment study
Lenze et al., JAMA, doi:10.1001/jama.2020.22760 (Peer Reviewed)
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial
Source   PDF   Share   Tweet
RCT 152 outpatients, 80 treated with fluvoxamine showing lower progression with treatment (0 of 80 versus 6 of 72 control).

Lenze et al., 11/12/2020, Double Blind Randomized Controlled Trial, peer-reviewed, 11 authors.
risk of disease progression, 92.7% lower, RR 0.07, p = 0.009, treatment 0 of 80 (0.0%), control 6 of 72 (8.3%), continuity correction due to zero event (with reciprocal of the contrasting arm), clinical deterioration over 15 days.
risk of hospitalization, 82.0% lower, RR 0.18, p = 0.009, treatment 1 of 80 (1.2%), control 5 of 72 (6.9%), COVID-19 hospitalization within 15 days, see supplemental appendix for details.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 3 studies
Please send us corrections, updates, or comments.